late cornified envelope pseudogene 4Genealiases: []
Q-omics provides the consensus-scored LCEP4 profile across patient tissues and cancer cell-line models. LCEP4 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, LCEP4 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, LCEP4 RNA expression shows 5,719 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight KIRC, HNSC, and LIHC as cancer lineages where LCEP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCEP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCEP4 survival associations across molecular data types. LCEP4 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCEP4 RNA expression–survival associations across cancer types. High LCEP4 expression shows unfavorable associations in KIRC, LIHC, MESO, LUAD, STAD and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .006). Together, the overview and detailed table identify KIRC as the clearest survival context for LCEP4 RNA expression.
This table summarizes LCEP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LCEP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCEP4 shows lower tumor expression in KIRC and higher tumor expression in HNSC, THCA, BRCA, LUSC and LIHC. The HNSC box plot shows higher LCEP4 RNA expression in tumor versus normal tissue (log2 FC = +0.118, t-test p = .001).
This table shows molecular features associated with LCEP4 in patient tissues and cancer cell lines. In patient samples, LCEP4 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set.
